Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/213448
Title: | Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry. |
Author: | Mostaghim, Anahita Minkove, Samuel Aguilar Company, Juan Ruiz, Isabel (Ruiz Camps) Eremiev-Eremiev, Simeon Dettorre, Gino M. Fox, Laura Tondini, Carlo Brunet, Joan Carmona-García, M. Carmen Lambertini, Matteo Bower, Mark Newsom-Davis, Thomas Sharkey, Rachel Pria, Alessia dalla Rossi, Maura Plaja, Andrea Salazar Soler, Ramón Sureda, Anna Prat Aparicio, Aleix Michalarea, Vasiliki Hemelrijck, Mieke Van Sita Lumsden, Ailsa Bertuzzi, Alexia Rimassa, Lorenza Rossi, Sabrina Rizzo, Gianpiero Pedrazzoli, Paolo Lee, Alvin J. X. Murphy, Cian Belessiotis, Katherine Diamantis, Nikolaos Mukherjee, Uma Pommeret, Fanny Stoclin, Annabelle Martinez-Vila, Clara Bruna, Riccardo Gaidano, Gianluca D’Avanzo, Francesca Gennari, Alessandra Athale, Janhavi Eichacker, Peter Pinato, David J. Torabi-Parizi, Parizad Cortellini, Alessio OnCovid study group |
Keywords: | COVID-19 Immunoteràpia Càncer SARS-CoV-2 COVID-19 Immunotheraphy Cancer SARS-CoV-2 |
Issue Date: | Feb-2024 |
Publisher: | Elsevier B.V. |
Abstract: | Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Results: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92). Conclusion: In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.ijid.2023.11.021 |
It is part of: | International Journal of Infectious Diseases, 2024, vol. 139, p. 13-20 |
URI: | http://hdl.handle.net/2445/213448 |
Related resource: | https://doi.org/10.1016/j.ijid.2023.11.021 |
ISSN: | 1201-9712 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
854718.pdf | 998.6 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License